Developing fluorescent imaging agents to guide cancer surgery
Near-infrared fluorescence imaging can guide tumour surgery, but tissue autofluorescence and light scattering reduce its sensitivity. These effects blur images and limit the clarity with which surgeons can visualise the tissue they need to operate on.
Fluonir is developing near-infrared fluorescent agents to help surgeons visualise tumour tissue during cancer surgery. Its WAZABY platform offers custom probes for cell imaging, animal studies and biomarker research.
What stands out about Fluonir
Successfully tested fluorescent agents in tumour-bearing mice for image-guided surgery of infiltrating head and neck tumours.
Source ↗Collaborated with Grenoble University Hospital and the Institute for the Advancement of Biosciences on fluorescence-guided surgery.
Source ↗Founded by Amélie Godard and Malorie Privat, whose doctoral research underpins its fluorescent imaging agents.
Source ↗Won the 2022 i-PhD Grand Prix through co-founder Amélie Godard's FLUONIR project.
Source ↗Supported by Linksium and DECA-BFC incubators in developing its fluorescent imaging venture.
Source ↗Selected for CNRS Innovation’s 12th RISE programme to develop its fluorescent-imaging venture with startup-creation support.
Source ↗Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.